Evaluation of performance of co crystals of mefloquine hydrochloride in tablet dosage form

References

• Meanwell NA. (2008). The emerging utility of co-crystals in drug discovery and development.. In: Macor JE, ed. Annual Report Medicinal Chemistry. Bridgewater: Elsevier Incorporation, 373–404.
   Google Scholar
• Vishweshwar P, McMahon JA, Bis JA, Zaworotko MJ. (2006). Pharmaceutical co-crystals. J Pharm Sci, 95:499–516.
   PubMed Web of Science ®Google Scholar
• Schultheiss N, Newman A. (2009). Pharmaceutical Cocrystals and Their Physicochemical Properties. Cryst Growth Des, 9:2950–2967.
   PubMed Web of Science ®Google Scholar
• Engel GL, Farid NA, Faul MM, Richardson LA, Winneroski LL. (2000). Salt form selection and characterization of LY333531 mesylate monohydrate. Int J Pharm, 198:239–247.
   PubMed Web of Science ®Google Scholar
• Hirsch CA, Messenger RJ, Brannon JL. (1978). Fenoprofen: Drug form selection and preformulation stability studies. J Pharm Sci, 67:231–236.
   PubMed Web of Science ®Google Scholar
• Bowker MJ. (2002). A procedure for salt selection and optimization.. In: Stahl HP, Wermuth CG. ed. Handbook of Pharmaceutical Salts Properties, Selection, and Use. Zürich: Verlag Helvetica Chimica Acta, 161–189.
   Google Scholar
• Saxena V, Panicucci R, Joshi Y, Garad S. (2009). Developability assessment in pharmaceutical industry: An integrated group approach for selecting developable candidates. J Pharm Sci, 98:1962–1979.
   PubMed Web of Science ®Google Scholar
• Morris KR, Fakes MG, Thakur AB, Newman AW, Singh AK, Venit JJ, Spagnuolo CJ, Serajuddin ATM. (1994). An integrated approach to the selection of optimal salt form for a new drug candidate. Int J Pharm, 105:209–217.
   Web of Science ®Google Scholar
• Serajuddin ATM, Pudipeddi M. (2002). Salt selection strategies.. In: Stahl HP, Wermuth CG. ed. Handbook of Pharmaceutical Salts Properties, Selection, and Use. Zürich: Verlag Helvetica Chimica Acta, 135–160.
   Google Scholar
• Guzmán HR, Tawa M, Zhang Z, Ratanabanangkoon P, Shaw P, Gardner CR et al. (2007). Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations. J Pharm Sci, 96:2686–2702.
   PubMed Web of Science ®Google Scholar
• Sandburg A, Abrahamsson B, Sjögren J. (1991). Influence of dissolution rate on the extent and rate of bioavailability of metoprolol. Int J Pharm, 68:167–177.
   Web of Science ®Google Scholar
• Meyer MC, Straughn AB, Mhatre RM, Shah VP, Williams RL, Lesko LJ. (1998). The relative bioavailability and in vivo-in vitro correlations for four marketed carbamazepine tablets. Pharm Res, 15:1787–1791.
   PubMed Web of Science ®Google Scholar
• Dressman JB, Amidon GL, Reppas C, Shah VP. (1998). Dissolution testing as a prognostic tool for oral drug absorption: Immediate release dosage forms. Pharm Res, 15:11–22.
   PubMed Web of Science ®Google Scholar
• Hörter D, Dressman JB. (2001). Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Adv Drug Deliv Rev, 46:75–87.
   PubMed Web of Science ®Google Scholar
• Kiang YH, Shi HG, Mathre DJ, Xu W, Zhang D, Panmai S. (2004). Crystal structure and surface properties of an investigational drug–a case study. Int J Pharm, 280:17–26.
   PubMed Web of Science ®Google Scholar
• Ling AR, Baker JL. (1893). Halogen derivatives of quinone. Part III. Derivatives of quinhydrone. J Chem Soc Trans, 63:1314–1327.
   Google Scholar
• Muster TH, Prestidge CA. (2002). Face specific surface properties of pharmaceutical crystals. J Pharm Sci, 91:1432–1444.
   PubMed Web of Science ®Google Scholar
• Peterson ML, Hickey MB, Zaworotko MJ, Almarsson O. (2006). Expanding the scope of crystal form evaluation in pharmaceutical science. J Pharm Pharm Sci, 9:317–326.
   PubMed Web of Science ®Google Scholar
• Chen AM, Ellison ME, Peresypkin A, Wenslow RM, Variankaval N, Savarin CG et al. (2007). Development of a pharmaceutical cocrystal of a monophosphate salt with phosphoric acid. Chem Commun (Camb), 419–421.
   PubMed Web of Science ®Google Scholar
• Childs SL, Zaworotko MJ. (2009). The re-emergence of cocrystals: The crystal clear writing is on the wall. Introduction to virtual special issue on pharmaceutical cocrystals. Cryst Growth Des, 9:4208–4211.
   Web of Science ®Google Scholar
• Aitipamula S, Chow PS, Tan RBH. (2009). Trimorphs of a pharmaceutical cocrystal involving two active pharmaceutical ingredients: Potential relevance to combination drugs. Cryst Eng Comm, 11:1823–1827.
   Web of Science ®Google Scholar
• Lu J, Rohani S. (2009). Preparation and characterization of theophylline-nicotnamide cocrystal. Org Process Res Dev, 13:1269–1275.
   Web of Science ®Google Scholar
• Bhatt PM, Azim Y, Thakur TS, Desiraju GR. (2009). Co-crystals of the anti-HIV drugs lamivudine and zidovudine. Cryst Growth Des, 9:951–957.
   Web of Science ®Google Scholar
• Noriyuki T. (2009). Cocrystal screening and its application in improvement of physicochemical properties of APIs. Pharm Tech Japan, 25:2543–2554.
   Google Scholar
• Li Z, Yang B-S, Jiang M, Eriksson M, Spinelli E, Yee N, Sensnayake C. (2009). A practical solid form screen approach to identify a pharmaceutical glutaric acid cocrystal for development. Org Process Res Dev, 13:1307–1314.
   Web of Science ®Google Scholar
• Gagniere E, Mangin D, Puel F, Bebon C, Klein J-P, Monnier O, Garcia E. (2009). Cocrystal formation in solution: In situ solute concentration monitoring of the two components and kinetic pathways. Cryst Growth Des, 9: 3376–3383.
   Web of Science ®Google Scholar
• Ainouz A, Authelin JR, Billot P, Lieberman H. (2009). Modeling and prediction of cocrystal phase diagrams. Int J Pharm, 374:82–89.
   PubMed Web of Science ®Google Scholar
• He G, Chow PS, Tan RBH. (2009). Predicting multicomponent crystal formation: The interplay between homomeric and heteromeric interactions. Cryst Growth Des, 9:4529–4532.
   Web of Science ®Google Scholar
• Cassidy AM, Gardner CE, Jones W. (2009). Following the surface response of caffeine cocrystals to controlled humidity storage by atomic force microscopy. Int J Pharm, 379:59–66.
   PubMed Web of Science ®Google Scholar
• Trask AV. (2007). An overview of pharmaceutical cocrystals as intellectual property. Mol Pharm, 4:301–309.
   PubMed Web of Science ®Google Scholar
• Yadav AV, Shete AS, Dabke AP, Kulkarni PV, Sakhare SS. (2009). Co-crystals: A novel approach to modify physicochemical properties of active pharmaceutical ingredients. Indian J Pharm Sci, 71:359–370.
   PubMed Web of Science ®Google Scholar
• Yadav AV, Dabke AP, Shete AS. (2010). Crystal engineering to improve physicochemical properties of mefloquine hydrochloride. Drug Dev Ind Pharm, 36:1036–1045.
   PubMed Web of Science ®Google Scholar
• Martin A, Swarbrick J, Cammarata A, Chun AHC. (1991). Physical pharmacy, physical and chemical principles in the pharmaceutical sciences. Bombay: Varghese Publishing House.
   Google Scholar
• Staniforth JN. (1990). Powder flow, the science of dosage forms designes. ELBS, 610–613.
   Google Scholar
• Govt. of India, Ministry of Health and Family Welfare. (1996). Indian Pharmacopoeia. Vol. 2. Delhi: The Controller of Publication, 242–243.
   Google Scholar
• Rager T, Hilfiker R. (2009). Stability domains of multi-component crystals in ternary phase diagrams. Z Phys Che, 223:793–813.
   Web of Science ®Google Scholar
• Childs SL, Rodríguez-Hornedo N, Reddy LS, Jayasankar A, Maheshwari C, McCausland L, Shipplett R, Stahly BC. (2008). Screening strategies based on solubility and solution composition generate pharmaceutically acceptable cocrystals of carbamazepine. Cryst Eng Comm, 10:856–864.
   Web of Science ®Google Scholar
• Blagden N, Berry DJ, Parkin A, Javed H, Ibrahim A, Gavan PT, De Matos LL, Seaton CC. (2008). Current directions in co-crystal growth. New J Chem, 32:1659–1672.
   Web of Science ®Google Scholar
• Stahl PH, Wermuth CG. (2002). Handbook of pharmaceutical salts: Properties, selection, and use. Germany: Wiley: Weinheim Publisher and Distributor.
   Google Scholar
• Steiner T. (1998). Hydrogen-bond distances to halide ions in organic and organometallic crystal structures: Up-to-date database study. Acta Cryst, B54:464–470.
   Web of Science ®Google Scholar
• Speakman JC. (1972). Acid salts of carboxylic acids, crystals with some “very short” hydrogen bonds. Struct & Bond, 12:141–199
   Google Scholar
• Obaleye JA, Caira MR, Tella AC. (2009). Synthesis, characterization and crystal structures of the tetrachlorocuprate and tetrabromocadmate salts of the antimalarial mefloquine. Struct Chem, 20:859–868.
   Web of Science ®Google Scholar
• Basavoju S, Boström D, Velaga SP. (2008). Indomethacin-saccharin cocrystal: Design, synthesis and preliminary pharmaceutical characterization. Pharm Res, 25:530–541.
   PubMed Web of Science ®Google Scholar
• Koji S, Noriyuki T, Ryusuke T, Yoshiki H, Katsuhide T.(2008). Dissolution improvement and the mechanism of the improvement from cocrystallization of poorly water-soluble compounds. Pharm Res, 25:2581–2592.
   PubMed Web of Science ®Google Scholar
• Yadav AV, Yadav VB, Shete AS. (2011). Experimental Biopharmaceutics and Pharmacokinetics. Pune: Nirali publications, 1.37–1.40.
   Google Scholar